Oppenheimer reiterated their outperform rating on shares of Trevi Therapeutics (NASDAQ:TRVI – Free Report) in a report issued on Thursday morning, Benzinga reports. The brokerage currently has a $9.00 target price on the stock. Separately, Needham & Company LLC reaffirmed a buy rating and set a $8.00 price target on shares of Trevi Therapeutics in […]